Fujifilm China will commercialize Cellvizio for gastroenterological and pulmonary applications in China and will increasingly integrate the Cellvizio platform into its commercial offers for advanced endoscopy systems.
With the recent Chinese FDA clearance for Cellvizio 100 series, Fujifilm China is now ideally positioned to launch Cellvizio for bilio-pancreatic applications as part of its leading endoscopic ultra-sound range of products.
"This expanded commercial partnership with Fujifilm in China is fully in line with our new commercialization strategy that aims at integrating Cellvizio into leading interventional platforms", said Sacha Loiseau, Founder and Chief Executive Officer of Mauna Kea Technologies.
"With our recent agreement with Cook Medical for urologic applications, we continue to further expand our strategic partnerships for a wide range of therapeutic applications for our unique endomicroscopy platform. We now have two solid partners to develop the important Chinese market."
With Fujifilm expanded commitment for 2016 and 2017, Cellvizio’s visibility and availability in the Asia-Pacific region will grow significantly.
Mauna Kea Technologies is a global medical device company focused on eliminating diagnostic and treatment uncertainties thanks to direct visualization at the cellular level.
The Company’s flagship product, Cellvizio, has received clearance to sell for a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.
